Transoma received FDA clearance for Sleuth AT Implantable Cardiac Monitoring System





Transoma Medical, manufacturer of Sleuth, the first wireless, automated implantable cardiac monitoring system has now received FDA marketing clearance on its second-generation product, Sleuth AT Cardiac Monitoring System.

The Sleuth products offer physicians the ability to diagnose patients with recurrent, unexplained fainting and abnormal heart rhythms quickly with its virtually unlimited memory capacity and hands-free downloading for the patient, while minimizing paperwork and practice workload.  With Sleuth AT, physicians can now choose to program the capture of high-quality ECG (electrocardiogram) strips at frequent intervals, providing a new level of insight into complex arrhythmias which are often asymptomatic and frequently changing. These captured ECG strips are automatically transferred to a 24/7 monitoring center, staffed by Certified Cardiac Technicians, who classify and notify physicians of the presence of a wide variety of cardiac arrhythmias such as ventricular tachycardia, bradycardia, supraventricular tachycardia and atrial fibrillation (AF).

Dr. Peter Kowey, Chief of Cardiology for Main Line Health said, The Transoma Sleuth AT system promises to provide an improved approach.